Transcatheter Technologies to expand platform with TRESILLO transcatheter mitral valve implantation system

REGENSBURG, Germany — Transcatheter Technologies GmbH, an emerging medical device company that has developed a “truly repositionable” transcatheter aortic valve implantation (TAVI) system for transapical and transfemoral implantation— Trinity —announced today that it is expanding its product family to include a transcatheter mitral valve implantation(TMVI)version as well: Tresillo.

“Per plan, we are expanding our platform technology to comprise a transfemoral and transapical Trinity TAVI system as well as a transfemoral Tresillo mitral valve implantation system. These three systems all share the same features. The premounted, valved stent is folded without the need of an outer sheath, thereby enabling precision controlled positioning and also allowing for repositioning if needed. This feature is most certainly unique to Trinity and Tresillo,” said Wolfgang Goetz, M.D., Ph.D., CEO.

Transcatheter mitral valve implantation is the next frontier for structural heart therapy. It is expected to revolutionize the way of treating mitral valve insufficiency. Approximately 3% of the population older than 60 years is suffering from symptomatic mitral valve regurgitation and may benefit from this interventional procedure while avoiding open-heart surgery.

“While we are very pleased with our product development variety and timelines,” added Dr. Goetz, “we are planning to further expand our pipeline of interventional innovations that are designed not only to be simpler to use but also facilitate superior patient safety and outcomes.”

Source: Source: Transcatheter Technologies GmbH